Plasma protein biomarkers for the prediction of CSF amyloid and tau and [18F]-flutemetamol PET scan result

Plasma protein biomarkers for the prediction of CSF amyloid and tau and [18F]-flutemetamol PET scan result

<strong>Background:</strong> Blood biomarkers may aid in recruitment to clinical trials of Alzheimer’s disease (AD) modifying therapeutics by triaging potential trials participants for amyloid positron emission tomography (PET) or cerebrospinal fluid (CSF) Aβ and tau tests. <strong&g...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Westwood, S, Baird, AL, Hye, A, Ashton, NJ, Nevado-Holgado, AJ, Anand, SN, Liu, B, Newby, D, Bazenet, C, Kiddle, SJ, Ward, M, Newton, B, Desai, K, Hehir, C, Zanette, M, Galimberti, D, Parnetti, L, Lleó, A, Baker, S, Narayan, VA, Van Der Flier, WM, Scheltens, P, Teunissen, CE, Visser, PJ, Lovestone, S
Μορφή:	Journal article
Έκδοση:	Frontiers Media 2018

Παρόμοια τεκμήρια

Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result
ανά: Sarah Westwood, κ.ά.
Έκδοση: (2018-12-01)

The influence of insulin resistance on CSF and plasma biomarkers of Alzheimer’s pathology
ανά: Westwood, S, κ.ά.
Έκδοση: (2017)

New CSF biomarkers on the block
ανά: Charlotte E Teunissen, κ.ά.
Έκδοση: (2016-09-01)

Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease
ανά: Rosha Babapour Mofrad, κ.ά.
Έκδοση: (2019-12-01)

Determining the molecular pathways underlying the protective effect of non-steroidal anti-inflammatory drugs for Alzheimer's disease: A bioinformatics approach
ανά: Nevado-Holgado, A, κ.ά.
Έκδοση: (2016)

CSF proteomic signature predicts progression to Alzheimer's disease dementia
ανά: Eleonora M. Vromen, κ.ά.
Έκδοση: (2022-01-01)

Blood-based proteomic biomarkers of Alzheimer’s disease pathology
ανά: Baird, A, κ.ά.
Έκδοση: (2015)

Determining the Molecular Pathways Underlying the Protective Effect of Non-Steroidal Anti-Inflammatory Drugs for Alzheimer's Disease: A Bioinformatics Approach
ανά: Alejo J Nevado-Holgado, κ.ά.
Έκδοση: (2017-01-01)

CSF Proteomic Alzheimer’s Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals
ανά: Betty Marije Tijms, κ.ά.
Έκδοση: (2021-08-01)

Establishing cutoff values for visual amyloid positivity in [18F]flutemetamol PET
ανά: Yong-Jin Park, κ.ά.
Έκδοση: (2025-01-01)

Amyloid-Targeting PET Tracer [18F]Flutemetamol Accumulates in Atherosclerotic Plaques
ανά: Sanna Hellberg, κ.ά.
Έκδοση: (2019-03-01)

White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation
ανά: Teunissen, C, κ.ά.
Έκδοση: (2018)

Clinical outcomes up to 9 years after [18F]flutemetamol amyloid-PET in a symptomatic memory clinic population
ανά: Lyduine E. Collij, κ.ά.
Έκδοση: (2023-11-01)

Clinical significance of focal ß-amyloid deposition measured by 18F-flutemetamol PET
ανά: Si Eun Kim, κ.ά.
Έκδοση: (2020-01-01)

Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status
ανά: Eline A. J. Willemse, κ.ά.
Έκδοση: (2021-01-01)

Variability of CSF Alzheimer's disease biomarkers: implications for clinical practice.
ανά: Stephanie J B Vos, κ.ά.
Έκδοση: (2014-01-01)

Thimet oligopeptidase as a potential CSF biomarker for Alzheimer's disease: A cross‐platform validation study
ανά: Yanaika S. Hok‐A‐Hin, κ.ά.
Έκδοση: (2023-07-01)

Red blood cell indices and anaemia as causative factors for cognitive function deficits and for Alzheimer's disease
ανά: Winchester, L, κ.ά.
Έκδοση: (2018)

Centiloid scaling for quantification of brain amyloid with [18F]flutemetamol using multiple processing methods
ανά: Mark R. Battle, κ.ά.
Έκδοση: (2018-12-01)

White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation
ανά: Charlotte E. Teunissen, κ.ά.
Έκδοση: (2018-03-01)

Binary classification of ¹⁸F-flutemetamol PET using machine learning: comparison with visual reads and structural MRI.
ανά: Vandenberghe, R, κ.ά.
Έκδοση: (2013)

Early-phase 18F-FP-CIT and 18F-flutemetamol PET were significantly correlated
ανά: Young-Sil An, κ.ά.
Έκδοση: (2021-06-01)

Temporal and anatomical distribution of 18F-flutemetamol uptake in canine brain using positron emission tomography
ανά: Taesik Yun, κ.ά.
Έκδοση: (2020-01-01)

PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases
ανά: Juhan Reimand, κ.ά.
Έκδοση: (2019-12-01)

Blood-based biomarker candidates of cerebral amyloid using PiB PET in non-demented elderly
ανά: Westwood, S, κ.ά.
Έκδοση: (2016)

18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.
ανά: Vandenberghe, R, κ.ά.
Έκδοση: (2010)

Software compatibility analysis for quantitative measures of [18F]flutemetamol amyloid PET burden in mild cognitive impairment
ανά: Hugh G. Pemberton, κ.ά.
Έκδοση: (2023-05-01)

Automatic lesion detection and segmentation in 18F-flutemetamol positron emission tomography images using deep learning
ανά: Chan Ju Ryu
Έκδοση: (2022-12-01)

Optimized dual-time-window protocols for quantitative [18F]flutemetamol and [18F]florbetaben PET studies
ανά: Fiona Heeman, κ.ά.
Έκδοση: (2019-03-01)

Cross-sectional and longitudinal analyses of outdoor air pollution exposure and cognitive function in UK Biobank
ανά: Cullen, B, κ.ά.
Έκδοση: (2018)

Commonly prescribed drugs associate with cognitive function: a cross-sectional study in UK Biobank
ανά: Nevado-Holgado, A, κ.ά.
Έκδοση: (2016)

Identification of a possible proteomic biomarker in Parkinson’s disease: discovery and replication in blood, brain and CSF
ανά: Winchester, L, κ.ά.
Έκδοση: (2022)

18F-flutemetamol PET/CT imaging in the diagnosis of mild cognitive impairment and Alzheimer's disease：a preliminary study
ανά: LEI Zhe, κ.ά.
Έκδοση: (2022-07-01)

Infrequent false positive [18F]flutemetamol PET signal is resolved by combined histological assessment of neuritic and diffuse plaques
ανά: Milos D. Ikonomovic, κ.ά.
Έκδοση: (2018-06-01)

Quantitative Evaluation of 18F-Flutemetamol PET in Patients With Cognitive Impairment and Suspected Alzheimer's Disease: A Multicenter Study
ανά: Hiroshi Matsuda, κ.ά.
Έκδοση: (2021-01-01)

Blood based proteomic biomarkers of Alzheimer’s disease pathology
ανά: Alison Louise Baird, κ.ά.
Έκδοση: (2015-11-01)

Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease
ανά: Carla M. Startin, κ.ά.
Έκδοση: (2019-03-01)

Red blood cell indices and anaemia as causative factors for cognitive function deficits and for Alzheimer’s disease
ανά: Laura M. Winchester, κ.ά.
Έκδοση: (2018-06-01)

Synaptic protein CSF levels relate to memory scores in individuals without dementia
ανά: Wesenhagen, KEJ, κ.ά.
Έκδοση: (2025)

Synaptic protein CSF levels relate to memory scores in individuals without dementia
ανά: Kirsten E. J. Wesenhagen, κ.ά.
Έκδοση: (2025-03-01)